Bolt Biotherapeutics, Inc. (BOLT)
BOLT moved a median of 0.00% 30 minutes after news, and -0.36% by the close. How BOLT actually reacts to news — the realized, point-in-time move the market made, measured across 373 labeled events over the last three years with zero look-ahead.
BOLT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 28% | 269 |
| 30-min | 0.00% | 44% | 351 |
| 60-min | -0.01% | 44% | 372 |
| to close | -0.36% | 38% | 370 |
| Middle 50% of BOLT reactions | -0.96% to +0.57% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 373 |
Half of all Bolt Biotherapeutics, Inc. news events land between -0.96% and +0.57% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BOLT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | -14.84% | 20% | -18.63% |
| Rating reiterations | 15 | 0.00% | 47% | -2.40% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how BOLT ranks against every other measured name →
That’s how BOLT usually reacts — get an email when it moves on news →Email me when BOLT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BOLT's baseline. Nothing else.
Recent BOLT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Bolt Biotherapeutics, For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | — | +0.56% | |
| Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | -7.27% | -13.53% | |
| Form 10-Q Bolt Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -7.27% | -13.53% | |
| Form 8-K Bolt Biotherapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -7.27% | -13.53% | |
| Form 8-K Bolt Biotherapeutics, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | — | -4.40% | |
| Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +3.43% | |
| Form 10-Q Bolt Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +3.43% | |
| Form 8-K Bolt Biotherapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.43% | |
| Form ARS Bolt Biotherapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.00% | +0.42% | |
| Form DEF 14A Bolt Biotherapeutics, For: Apr 27 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.42% | |
| Form DEFA14A Bolt Biotherapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +0.42% | |
| Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -2.74% | |
| Form 10-K Bolt Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -2.74% | |
| Form 8-K Bolt Biotherapeutics, For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.74% | |
| Form S-8 Bolt Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -2.74% | |
| Bolt Biotherapeutics to Participate in Upcoming March Conferences | Press release | GlobeNewswire | -0.14% | +1.60% | |
| Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -2.16% | — | |
| Form 10-Q Bolt Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.16% | — | |
| Form 8-K Bolt Biotherapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -2.16% | — | |
| Form 8-K Bolt Biotherapeutics, For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | -2.73% | +3.71% | |
| Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027 | Press release | GlobeNewswire | -2.38% | -1.78% | |
| Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | — | -3.01% | |
| Form 10-Q Bolt Biotherapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -3.01% | |
| Form 8-K Bolt Biotherapeutics, For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | — | -3.01% | |
| Form 8-K Bolt Biotherapeutics, For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | -5.63% | -5.25% | |
| Form 8-K Bolt Biotherapeutics, For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.20% | -3.78% | |
| Form 8-K Bolt Biotherapeutics, For: May 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -2.77% | |
| Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -4.11% | |
| Form 10-Q Bolt Biotherapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | -4.11% | |
| Form 8-K Bolt Biotherapeutics, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -4.11% | |
| Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates | Press release | GlobeNewswire | +0.00% | +2.78% | |
| Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025 | Press release | GlobeNewswire | -0.03% | -2.53% | |
| Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 | Press release | GlobeNewswire | +0.00% | +4.00% | |
| Form ARS Bolt Biotherapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.03% | +0.80% | |
| Form DEF 14A Bolt Biotherapeutics, For: May 27 | SEC filing · Form DEF | SEC EDGAR | +0.60% | +1.40% | |
| Form 8-K Bolt Biotherapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | — | +2.64% | |
| Form PRE 14A Bolt Biotherapeutics, For: May 27 | SEC filing · Form PRE | SEC EDGAR | -3.62% | -3.77% | |
| Form DEF 14A Bolt Biotherapeutics, For: May 27 | SEC filing · Form DEF | SEC EDGAR | -3.62% | -3.77% | |
| Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 | Press release | GlobeNewswire | +0.00% | +4.69% | |
| Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | -1.06% | |
| Form 10-K Bolt Biotherapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -1.06% | |
| Form 8-K Bolt Biotherapeutics, For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.06% | |
| Form S-8 Bolt Biotherapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -1.06% | |
| Bolt Biotherapeutics to Participate in Upcoming March Conferences | Press release | GlobeNewswire | +0.84% | -2.33% | |
| Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. | Press release | GlobeNewswire | +3.23% | +3.46% | |
| Form 8-K Bolt Biotherapeutics, For: Jan 02 | SEC filing · Form 8-K | SEC EDGAR | -1.94% | +0.69% | |
| Form 8-K Bolt Biotherapeutics, For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.55% | |
| Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.60% | -2.06% | |
| Form 10-Q Bolt Biotherapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.60% | -2.06% | |
| Form 8-K Bolt Biotherapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +1.60% | -2.06% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BOLT section they belong to.
Where else BOLT is measured.
BOLT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Bolt Biotherapeutics, Inc.'s median reaction calculated?
Every labeled BOLT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 373 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of BOLT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BOLT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.